Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics

De novo-designed antivenom for snakebite

BioCentury | Sep 6, 2022
Distillery Therapeutics

Targeting three thalamic circuits in Parkinson's disease

BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Oct 18, 2021
Regulation

New nasal spray option for dry eye as Oyster Point wins FDA nod

Oyster Point’s Tyrvaya offers dosing advantage over artificial tears
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin aims to tamp down neuron excitability with its conditionally active ion channels
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

With four liquidity events already from its first fund, Vida wants its second to deliver cures
Items per page:
1 - 10 of 50